Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer

Matsuo, Masaki; Baba, Shingo; Hashimoto, Kazuki; Isoda, Takuro; Kitamura, Yoshihisa; Kogo, Ryunosuke; Jiromaru, Rina; Hongo, Takahiro; Manako, Tomomi; Nakagawa, Takashi

doi:10.21873/anticanres.16148

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who tested positive for [ 18 F]FDG PET/CT had a significantly worse prognosis than those who were negative for initial RIT. This demonstrates that [ 18 F] FDG PET/CT plays an important role in both the diagnosis and prognostic prediction of RIT-refractory disease in DTC patients [41].…”

Section: Differentiated Thyroid Cancermentioning

confidence: 87%

“…Molecular imaging plays an important role in the analysis and treatment of various types of thyroid cancer [41]. Differentiated thyroid carcinoma (DTC) is the most prevalent endocrine tumor and typically has a favorable prognosis, except when it becomes refractory to radioiodine therapy (RIT).…”

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

“…Identifying cases with a poor prognosis usually occurs after multiple RITs, emphasizing the importance of early and dependable predictive tools. Matsuo et al investigated whether [ 18 F]FDG PET/ CT, when combined with initial RIT, could identify earlystage patients with a poor prognosis among those with highrisk DTC [41]. Patients who tested positive for [ 18 F]FDG PET/CT had a significantly worse prognosis than those who were negative for initial RIT.…”

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

See 2 more Smart Citations

Endocrinology application of molecular imaging: current role of PET/CT

Calderoni,

Giovanella,

Fanti

2024

J Endocrinol Invest

View full text Add to dashboard Cite

Background In recent years, nuclear medicine imaging methods have proven to be of paramount importance in a wide variety of diseases, particularly in oncology, where they are crucial for assessing the extent of disease when conventional methods fall short. Moreover, nuclear imaging modalities are able to better characterize lesions using target agents related to specific pathways (e.g. glucose metabolism, cellular proliferation, amino acid transport, lipid metabolism, specific receptor ligands). The clinical presentation of endocrine diseases encompasses a broad spectrum of sign and symptoms. Moreover, endocrine tumors show varying degrees of aggressiveness from well differentiated and indolent to highly aggressive cancers, respectively. Rationale With the application of new medicinal radio-compounds and increasingly advanced tomographic imaging technology, the utility of Positron Emission Tomography/Computed Tomography (PET/CT) in the field of endocrine diseases is expanding. Aim This review aims to analyze and summarize the primary indications of PET/CT, providing a practical approach for clinicians. A comprehensive literature search on PubMed was conducted to provide an updated overview of the available evidence regarding the use of PET/CT in endocrinology. Within this review, we will discuss the applications of PET/CT, compare different radiopharmaceuticals and highlight the uptake mechanism, excluding neuroendocrine carcinomas from discussion. Conclusions PET/CT is a valuable tool in diagnosing and managing endocrine disorders due to its capacity to furnish both functional and anatomical information, facilitate early lesion detection, guide treatment decisions, and monitor treatment response. Its non-invasive nature and precision make it an integral component of modern endocrine healthcare. This review aims to provide physicians with a clear perspective on the role of PET/CT imaging, discussing its emerging opportunities and appropriateness of use in endocrinological diseases.

show abstract

Section: Differentiated Thyroid Cancermentioning

confidence: 87%

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

Section: Differentiated Thyroid Cancermentioning

confidence: 99%

See 1 more Smart Citation

Endocrinology application of molecular imaging: current role of PET/CT

Calderoni,

Giovanella,

Fanti

2024

J Endocrinol Invest

View full text Add to dashboard Cite

show abstract

Role of [18F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma

Zajkowska,

Cegla,

Dedecjus

2024

Cancer Imaging

View full text Add to dashboard Cite

Follicular cell-derived thyroid carcinomas constitute the majority of thyroid malignancies. This heterogeneous group of tumours includes well differentiated, poorly differentiated, and undifferentiated forms, which have distinct pathological features, clinical behaviour, and prognosis. Positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose combined with computed tomography ([18F]FDG PET/CT) is an imaging modality used in routine clinical practice for oncological patients. [18F]FDG PET/CT has emerged as a valuable tool for identifying patients at high risk of poor clinical outcomes and for facilitating individualized clinical decision-making. The aim of this comprehensive review is to summarize current knowledge regarding the role of [18F]FDG PET/CT in primary diagnosis, treatment, and follow-up of follicular cell-derived thyroid carcinomas considering the degree of differentiation. Controversial issues, including significance of accidentally detected [18F]FDG uptake in the thyroid, the role of [18F]FDG PET/CT in the early assessment of response to molecular targeted therapies, and its prognostic value are discussed in detail.

show abstract

Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review

Wang,

Lu,

Liu

2024

Front. Endocrinol.

View full text Add to dashboard Cite

It is well established that patients with the most differentiated thyroid cancers have a good prognosis, whereas when the disease develops into radio-iodine refractory thyroid cancer (RAIR) their prognosis is poor and the 10-year survival rate is low. At present, the therapeutic methods for RAIR are limited and have low efficacy. As a consequence, several models have been developed for predicting RAIR. The aim of this review was to describe recent developments regarding the factors that influence and predict the occurrence of RAIR. Many variables including demographic characteristics, tumor clinicopathology, serology changes, disease characteristics, and PET/CT results have been shown to be independent factors that influence the development of RAIR. The cut-off value derived from multivariate prediction models therefore effectively predicts the onset of RAIR. However, the current models for predicting RAIR were obtained through retrospective studies, and the prospective prediction studies are needed in the future to confirm their validity.

show abstract

Utility of FDG PET at the Initial Radioiodine Therapy in Differentiated Thyroid Cancer

Cited by 3 publications

References 0 publications

Endocrinology application of molecular imaging: current role of PET/CT

Endocrinology application of molecular imaging: current role of PET/CT

Role of [18F]FDG PET/CT in the management of follicular cell-derived thyroid carcinoma

Current status of the prediction for radio-iodine refractory thyroid cancer: a narrative review

Contact Info

Product

Resources

About